GTH Genetron Holdings Ltd

Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that management will present and host 1x1 investor meetings at six upcoming investor and industry conferences.

Details related to the team’s participation are as follows:

Conference: China Renaissance Healthcare and Life Sciences Leadership SummitLocation: Shanghai, ChinaRoundtable Discussion: October 30 at 11:55 am CST (China Standard Time)

Conference: CICC Investment Forum (Beijing) 2020Location: Beijing, ChinaPanel Discussion Date & Time: November 12 at 3:30 pm CST

Conference: BioCentury and BayHelix 7th China Healthcare SummitDates: November 9-13

Conference: Goldman Sachs Asia Pacific Healthcare Conference 2020Dates: November 16–17

Conference: Bernstein's Inaugural Operational Decisions Conference (ODC)Presentation Date/Time: November 17 at 10:00 am EST (Eastern Standard Time)

Conference: Canaccord Genuity's MedTech and Diagnostics ForumPresentation Date/Time: November 19 at 8:30 am EST

About Genetron Holdings Limited

Genetron Holdings Limited (“Genetron Health” or the “Company”) (Nasdaq:GTH) is a leading precision oncology platform company in China that specializes in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment. The Company has developed a comprehensive oncology portfolio that covers the entire spectrum of cancer management, addressing needs and challenges from early screening, diagnosis and treatment recommendations, as well as continuous disease monitoring and care. Genetron Health also partners with global biopharmaceutical companies and offers customized services and products. For more information, please visit ir.genetronhealth.com.

Safe Harbor Statement

This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the Company’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and a number of factors could cause actual results to differ materially from those contained in any forward-looking statement. In some cases, forward-looking statements can be identified by words or phrases such as “may”, “will,” “expect,” “anticipate,” “target,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. Further information regarding these and other risks, uncertainties or factors is included in the Company’s filings with the SEC. All information provided in this press release is as of the date of this press release, and the Company does not undertake any duty to update such information, except as required under applicable law.

Investor Relations ContactsUS:Hoki LukHead of Investor RelationsEmail: hoki.luk@genetronhealth.comPhone: +1 (408) 204-5343

Stephanie CarringtonWestwicke, an ICR CompanyEmail: Stephanie.Carrington@westwicke.comPhone: +1 (646) 277-1282

Asia:Bill ZimaICR, Inc.Email: bill.zima@icrinc.comGenetronIR@icrinc.com 

Media Relations ContactEdmond LococoICREdmond.Lococo@icrinc.comMobile: +86 138-1079-1408genetron.pr@icrinc.com